Solid nanoparticle with inorganic coating
A nanoparticle having a solid core comprising a biologically active substance, said core being enclosed by an inorganic coating, a method for preparing the nanoparticle, and the use of the nanoparticle in therapy. A kit comprising the nanoparticle and a pharmaceutical composition comprising the nanoparticle.
1 . A method of preparing a plurality of coated particles for use in a controlled or delayed release pharmaceutical composition for use in the treatment of cancer, wherein the plurality of coated particles comprises particles having a size that is from 0.1 μm to 50 μm, said coated particles having a solid core comprising one or more anticancer agent, said solid core being enclosed by one or more metal oxide materials, wherein the method comprises the sequential steps of:
(1) applying an initial coating of at least one metal oxide to said solid cores in an atomic layer deposition reactor;
(2) discharging the coated particles from the reactor and subjecting the coated particles to agitation to disaggregate particle aggregates formed during step (1);
(3) reintroducing the disaggregated, coated particles from step (2) into an atomic layer deposition reactor and applying a further coating of at least one metal oxide to the reintroduced particles;
(4) optionally repeating steps (2) and (3) one or more times to increase total thickness of the one or more metal oxide materials that enclose said solid core; and
(5) recovering the disaggregated, coated particles.
2 . A method of preparing a controlled or delayed release pharmaceutical composition, comprising:
a. a plurality of coated particles as defined in claim 1 ; and
b. a pharmaceutically acceptable carrier,
wherein the method comprises the sequential steps (1) to (5) as defined in claim 1 , followed by admixing the coated particles obtained from step (5) with said pharmaceutically acceptable carrier to form said pharmaceutical composition.
3 . The method of claim 2 , wherein the pharmaceutically acceptable carrier is a liquid.
4 . The method of claim 2 , wherein the composition is in the form of a sterile injectable or infusible suspension of the coated particles in a non-toxic parenterally-acceptable diluent.
5 . The method of claim 4 , wherein the composition is in the form of a sterile aqueous or oleaginous suspension.
6 . The method of claim 1 , wherein steps (2) and (3) are repeated at least once.
7 . The method of claim 1 , wherein steps (2) and (3) are repeated at least twice.
8 . The method of claim 1 , wherein steps (2) and (3) are repeated three times.
9 . The method of claim 1 , wherein steps (2) and (3) are repeated up to nine times.
10 . The method of claim 1 , wherein the one or more metal oxide materials are selected from the group consisting of aluminium oxide, titanium dioxide, iron oxide, gallium oxide, magnesium oxide, zinc oxide, niobium oxide, hafnium oxide, tantalum oxide, lanthanum oxide, zirconium dioxide, silicon dioxide, and combinations thereof.
11 . The method of claim 1 , wherein the one or more metal oxide materials are selected from the group consisting of aluminium oxide, titanium dioxide, zinc oxide, and combinations thereof.
12 . The method of claim 1 , wherein the one or more metal oxide materials is zinc oxide.
13 . The method of claim 1 , wherein the solid core consists essentially of said one or more anticancer agent.
14 . The method of claim 1 , wherein said one or more anticancer agent in the solid core is either in admixture with one or more other substances selected from excipients and biologically active ingredients, or is free from said other substances.
15 . The method of claim 1 , wherein a total thickness of all the metal oxide coatings is from 0.1 nm to 500 nm.
16 . The method of claim 1 , wherein a total thickness of all the metal oxide coatings is from 0.1 nm to 100 nm.
17 . The method of claim 1 , wherein a total thickness of all the metal oxide coatings is from 0.1 nm to 50 nm.
18 . A plurality of coated particles for the treatment of cancer, wherein the plurality of coated particles comprises particles having a size that is from 0.1 μm to 50 μm, said coated particles having a solid core comprising one or more anticancer agent, said solid core being enclosed by one or more metal oxide materials to enable a therapeutically effective controlled or delayed release of said one or more anticancer agent from the coated particles in said pharmaceutical composition, the plurality of coated particles being prepared according to a process comprising the sequential steps of:
(1) applying a coating of at least one metal oxide to said solid cores in an atomic layer deposition reactor;
(2) discharging the coated particles from the reactor and subjecting the coated particles to agitation to disaggregate particle aggregates formed during step (1);
(3) reintroducing the disaggregated, coated particles from step (2) into an atomic layer deposition reactor and applying a further coating of at least one metal oxide to the reintroduced particles;
(4) optionally repeating steps (2) and (3) one or more times to increase total thickness of the one or more metal oxide materials that enclose said solid core; and
(5) recovering the disaggregated, coated particles, wherein the controlled or delayed release of said one or more anticancer agent from the coated particles is provided by the process steps (1) to (3), and (4), if performed.
19 . The plurality of coated particles of claim 18 , wherein the one or more metal oxide materials are selected from the group consisting of aluminium oxide, titanium dioxide, iron oxide, gallium oxide, magnesium oxide, zinc oxide, niobium oxide, hafnium oxide, tantalum oxide, lanthanum oxide, zirconium dioxide, and/or silicon dioxide.
20 . The plurality of coated particles of claim 18 , wherein the one or more metal oxide materials are selected from the group consisting of aluminium oxide, titanium dioxide and/or zinc oxide.
21 . The plurality of coated particles of claim 18 , wherein the one or more metal oxide materials is zinc oxide.
22 . The plurality of coated particles of claim 18 , wherein the solid core consists essentially of said one or more anticancer agent.
23 . The plurality of coated particles of claim 18 , wherein a total thickness of all the metal oxide coatings is from 0.1 nm to 50 nm.
24 . A controlled or delayed release pharmaceutical composition, comprising:
a. a plurality of coated particles as defined in claim 18 ; and
b. a pharmaceutically acceptable carrier,
the pharmaceutical composition being prepared by admixing said plurality of coated particles with said pharmaceutically acceptable carrier to form said pharmaceutical composition.
25 . The pharmaceutical composition of claim 24 , wherein the pharmaceutically acceptable carrier is a liquid.
26 . The pharmaceutical composition of claim 24 , wherein the composition is in the form of a sterile injectable or infusible suspension of the coated particles in a non-toxic parenterally-acceptable diluent.
27 . The pharmaceutical composition of claim 24 , wherein the composition is in the form of a sterile aqueous or oleaginous suspension.
28 . The pharmaceutical composition of claim 24 , wherein steps (2) and (3) are repeated at least once.
29 . The pharmaceutical composition of claim 24 , wherein steps (2) and (3) are repeated at least twice.
30 . The pharmaceutical composition of claim 24 , wherein steps (2) and (3) are repeated three times.
31 . The pharmaceutical composition of claim 24 , wherein steps (2) and (3) are repeated up to nine times.
32 . The pharmaceutical composition of claim 24 , wherein the one or more metal oxide materials is zinc oxide.
33 . The pharmaceutical composition of claim 24 , wherein the solid core consists essentially of said one or more anticancer agent.
34 . The pharmaceutical composition of claim 24 , wherein said one or more anticancer agent in the solid core is either in admixture with one or more other substances selected from excipients and biologically active ingredients, or is free from said other substances.
35 . The pharmaceutical composition of claim 24 , wherein a total thickness of all the metal oxide coatings is from 0.1 nm to 500 nm.
36 . The pharmaceutical composition of claim 24 , wherein a total thickness of all the metal oxide coatings is from 0.1 nm to 100 nm.
37 . The pharmaceutical composition of claim 24 , wherein a total thickness of all the metal oxide coatings is from 0.1 nm to 50 nm.
38 . A method of treatment of cancer comprising:
parenterally administering to a cancer patient a therapeutically effective amount of the pharmaceutical composition according to claim 24 .
39 . The method of claim 38 , wherein said parenterally administering is carried out by inhalation, injection or infusion.
40 . The method of claim 38 , wherein said parenterally administering is carried out by intravenous, intraarterial, intraosseous, intramuscular, intracerebral, intracerebroventricular, intrasynovial, intrasternal, intrathecal, intralesional, intracranial, intratumoral, intracutaneous or subcutaneous injection or infusion.
41 . The method of claim 38 , wherein said parenterally administering is carried out by intratumoral injection.
42 . The pharmaceutical composition of claim 24 , wherein said one or more anticancer agent is selected from the group consisting of an antineoplastic agent, an immunosuppressant, an immunostimulant, a chemotherapeutic, a growth factor, an immunological agent, a bisphosphonate, a prostaglandin, a radio-pharmaceutical, a hormone, a sex hormone, a protein, a peptide, a polypeptide, a steroid, a vaccine, an anti-inflammatory agent, an antibiotic, an antiviral agent and a bacteriostatic agent.
43 . The pharmaceutical composition of claim 24 , wherein said one or more anticancer agent is selected from the group consisting of cisplatin, medroxyprogesterone, methylprednisolone, paclitaxel, beclomethasone, budesonide, cefotaxime, cephalexin, ciprofloxacin, clarithromycin, cyclosporin, etoposide, finasteride, fluconazole, flunisolide, isotretinoin, isradipine, mometasone, norfloxacin and triamcinolone.
44 . The method of claim 38 , wherein said one or more anticancer agent is selected from the group consisting of an antineoplastic agent, an immunosuppressant, an immunostimulant, a chemotherapeutic, a growth factor, an immunological agent, a bisphosphonate, a prostaglandin, a radio-pharmaceutical, a hormone, a sex hormone, a protein, a peptide, a polypeptide, a steroid, a vaccine, an anti-inflammatory agent, an antibiotic, an antiviral agent and a bacteriostatic agent.
45 . The method of claim 38 , wherein said one or more anticancer agent is selected from the group consisting of cisplatin, medroxyprogesterone, methylprednisolone, paclitaxel, beclomethasone, budesonide, cefotaxime, cephalexin, ciprofloxacin, clarithromycin, cyclosporin, etoposide, finasteride, fluconazole, flunisolide, isotretinoin, isradipine, mometasone, norfloxacin and triamcinolone.
46 . The method of claim 41 , wherein said one or more anticancer agent is selected from the group consisting of cisplatin, medroxyprogesterone, methylprednisolone and paclitaxel.
47 . The method of claim 41 , wherein said one or more anticancer agent is cisplatin.